Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Kavitha Yaddanapudi · UNIVERSITY OF LOUISVILLE · 2024 · $335,530 — Lung cancer kills more people than any other type of cancer, including more than 130,000 people each year in the United States. Non-small cell lung cancer (NSCLC) is the most common subtype (82% of all lung cancers) and can arise from squamous or non-squamous lung epithelial cells. Combination treat…
Zhijian Qian · UNIVERSITY OF FLORIDA · 2024 · $385,748 — Abstract Acute myeloid leukemia (AML) is one of the most common and fatal forms of hematological malignancies caused by gene mutations and genomic rearrangements. The cure rates for AML patients have not significantly improved for decades. The molecular mechanisms underlying the pathogenesis of AML …
Melissa Hladek · JOHNS HOPKINS UNIVERSITY · 2024 · $195,390 — PROJECT SUMMARY/ ABSTRACT Kidney transplantation (KT) is a growing treatment for older adults with end-stage renal disease (ESRD), but there is vast heterogeneity in KT outcomes. Older adults are more likely to be listed as inactive (on the waitlist but ineligible for KT), which is associated with i…
Guogen Shan · UNIVERSITY OF FLORIDA · 2024 · $289,505 — Project Summary/Abstract Alzheimer’s disease (AD) is characterized by heterogeneity in sex, race, APOE ε4 status, and tau. APOE ε4 status has been used to stratify AD patients in clinical trials (e.g., the aducanumab trial). Women with AD have faster cognitive decline compared to men with AD from lo…
Janet Ellen Dancey · QUEEN'S UNIVERSITY AT KINGSTON · 2024 · $2,333,866 — Summary The transformational advances in cancer biology and technologies to characterize cancers at a molecular level, combined with the rapid expansion of novel drugs and cellular therapies, mandates a fundamental re- evaluation of clinical trial design and delivery to ensure maximal patient and so…
MAGDALENA ELZBIETA SOBIESZCZYK · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2024 · $188,707 — PROJECT ABSTRACT This is a renewal application from the Columbia University Irving Medical Center (CUIMC) for a post-doctoral training grant in Infectious Diseases entitled “Columbia Integrated Training Program in Infectious Disease Research (TP-IDR)”. Drs. Anne-Catrin Uhlemann and Magdalena Sobiesz…
Burcin Ekser · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · 2024 · $460,458 — Biliary liver diseases, such as primary sclerosing cholangitis (PSC), are characterized by the damage and proliferation of cholangiocytes that are a key link between biliary injury and the subepithelial fibrosis, manifesting chronic hepatobiliary injury that represents a major clinical challenge. Wh…
Ricardo Castillo Neyra · UNIVERSITY OF PENNSYLVANIA · 2024 · $633,891 — Spatially Responsive Mass Vaccination Campaigns for Urban Rabies SUMMARY Epidemics of vaccine-preventable zoonotic diseases are ongoing in major urban centers across Latin America and worldwide. Mass vaccination campaigns can prevent and control epidemics of infectious diseases among humans and anim…
Songi Han · UNIVERSITY OF CALIFORNIA SANTA BARBARA · 2024 · $711,751 — PROJECT SUMMARY The bottleneck for tauopathy therapy development is the lack of validated tauopathy models, mouse, cell or in vitro. This is reflected in the current reality that tauopathy-specific fibril structures solved by cryo-EM from post mortem patient brain tissue have never been replicated o…
Julie Kay Andersen · BUCK INSTITUTE FOR RESEARCH ON AGING · 2024 · $625,485 — PROJECT SUMMARY / ABSTRACT Losses in protein homeostasis associated with accumulation of damaged, misfolded and aggregated proteins is a characteristic feature of aging and many age-related neurodegenerative diseases. We hypothesize that this may in part be driven by age-related dysfunctions in auto…
Wenquan Ou · UNIV OF MARYLAND, COLLEGE PARK · 2024 · $235,233 — Project Summary/Abstract Breast cancer is the second leading cause of cancer-related deaths of American women. In particular, no targeted therapy is clinically available for nearly all triple negative breast cancer (TNBC). Cancer arises as a result of accumulating genetic alterations. Therefore, de…
Hunter B Fraser · STANFORD UNIVERSITY · 2024 · $681,479 — Project Summary Despite a great deal of research, we have discovered surprisingly little about the genetic basis of uniquely human traits—largely due to the ethical and practical considerations that severely limit comparisons between humans and other primates. To advance this field, we have integrat…
Jackson Mace · JOHNS HOPKINS UNIVERSITY · 2024 · $48,974 — Project Summary Nearly three million people worldwide are currently living with multiple sclerosis (MS), a complex neurological disease that primarily affects individuals between 20-45 years of age. MS is characterized by peripheral immune cell infiltration into the central nervous system (CNS) with…
Ross I. Berbeco · DANA-FARBER CANCER INST · 2024 · $566,253 — Project Summary Recent preclinical and clinical results have demonstrated the safety and efficacy of nanoparticle-amplified radiation therapy. In parallel, MR-guided radiation therapy is an emerging paradigm that would benefit from specific contrast agents. This Academic- Industrial Partnership will…
DOUGLAS K GRAHAM · UNIV OF NORTH CAROLINA CHAPEL HILL · 2024 · $306,926 — TYRO3 is a member of the TAM (TYRO3, AXL, MERTK) family of receptor tyrosine kinases. All three family members are aberrantly expressed in cancer cells, where they function to promote cell survival, mediate resistance to a variety of cytotoxic chemotherapies and molecularly-targeted agents and have …
Marina Y Konopleva · UNIVERSITY OF FLORIDA · 2024 · $480,430 — Targeting the anti-apoptotic Bcl-2 family proteins is a promising therapeutic strategy for cancer and has been validated by the FDA approval of the Bcl-2 selective inhibitor, venetoclax, for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). Given the well-document…
Cardinale B Smith · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2024 · $642,048 — PROJECT SUMMARY/ABSTRACT The outcomes of advanced solid cancer patients remain poor, particularly among minorities. Although patient- and system-level factors are important contributors to cancer disparities, physician-related factors such as implicit bias also play a significant role. While rare ca…
Luksana Chaiswing · UNIVERSITY OF KENTUCKY · 2024 · $332,489 — PROJECT SUMMARY Radiation therapy (RT) is widely used to treat localized prostate cancer (PCa). However, cancer cells often develop resistance to RT through unknown mechanisms, resulting in cancer recurrence. To improve RT, there is a dire need to uncover cellular events that cause cells to become r…
Jareen Meinzen-Derr · CINCINNATI CHILDRENS HOSP MED CTR · 2024 · $588,358 — PROJECT SUMMARY Upon diagnosis of hearing loss, parents/caregivers of children who are deaf/hard-of-hearing (DHH) make decisions around numerous approaches to language and communication development. Despite strong efforts to improve long-term outcomes, DHH children continue to fall short of age-appr…
Saurabh Suhas Thosar · OREGON HEALTH & SCIENCE UNIVERSITY · 2024 · $612,666 — Project Summary Hypertension (HTN) is a leading cause of morbidity and mortality in the United States and affects approximately 45% of US adults. Blood pressure (BP) is almost invariably higher during the day; however, the relative drop in overnight BP is a better predictor of overall CV risk than d…